



Express Mail No.: EV473971339US
Sheet 1 of 3

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.
6750-189-999

APPLICATION NO.
10/567,702

APPLICANT
Richard Kim

U.S. FILING DATE
August 21, 2006

ART UNIT
1642

U.S. PATENT DOCUMENTS

| *Examiner Initial | Document Number | Date mm/dd/yy | Name Of Patentee Or Applicant Of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear |
|-------------------|-----------------|---------------|---|---|
| | | | | |

FOREIGN PATENT DOCUMENTS

| | Foreign Patent Document Country Code, Number, Kind Code (If Known) | Date mm/dd/yy | Name Of Patentee Or Applicant Of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T |
|--|--|---------------|---|---|---|
| | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published) | T |
|-------------------|---|---|
| | C01 AARANSON, 1991, "Growth factors and cancer." <i>Science</i> 254:1146-53 | |
| | C02 BASELGA et al., 2001, "Mechanism of action of trastuzumab and scientific update." <i>Semin Oncol.</i> 28:4-11 | |
| | C03 BASELGA, 2001, "The EGFR as a target for anticancer therapy--focus on cetuximab." <i>Eur. J. Cancer</i> 37: S16-22 | |
| | C04 CARRAWAY & CANTLEY, "A new acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling." 1994, <i>Cell</i> 78:5-8 | |
| | C05 CIARDELLO et al., 2002, "A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor." <i>Clin. Cancer Res.</i> 7:2958-70 | |
| | C06 COUSSENS et al., 1985, "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene." <i>Science</i> 230:1132-9 | |
| | C07 DEBONO et al., 2002, "The ErbB receptor family: a therapeutic target for cancer." <i>Trends in Mol. Med.</i> 8(4): S19-S26 | |
| | C08 FALLS, 2003, "Neuregulins: functions, forms, and signaling strategies." <i>Exp. Cell. Res.</i> 284(1): 14-30 | |
| | C09 FAN et al., 1994, <i>J. Biol. Chem.</i> 269:27585-602 | |
| | C10 GENBANK Accession No. AF001455, "Homo sapiens proto-oncogene protein (c-erb-2) gene, exon 1" | |
| | C11 GENBANK Accession No. AY207002, "Homo sapiens neuregulin 1 isoform 4 (NRG1) mRNA, partial cds, alternatively spliced." | |
| | C12 GENBANK Accession No. NM-004983, "Homo sapiens neuregulin 2 (NRG2), transcript variant 1, mRNA." | |
| | C13 GENBANK Accession No. NM-013981, "Homo sapiens neuregulin 2 (NRG2), transcript variant 2, mRNA." | |
| | C14 GENBANK Accession No. NM-013982, "Homo sapiens neuregulin 2 (NRG2), transcript variant 3, mRNA." | |
| | C15 GENBANK Accession No. NM-012082, "Homo sapiens neuregulin 2 (NRG2), transcript variant 4, mRNA." | |
| | C16 GENBANK Accession No. NM-013984, "Homo sapiens neuregulin 2 (NRG2), transcript variant 5, mRNA." | |
| | C17 GENBANK Accession No. NM-013985, "Homo sapiens neuregulin 2 (NRG2), transcript variant 6, mRNA." | |
| | C18 GENBANK Accession No. NM-031507, "Rattus norvegicus epidermal growth factor receptor (Egfr), mRNA." | |

EXAMINER
NYI-3927254v1

/Anne Holleran/

DATE CONSIDERED 12/22/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./



Express Mail No.: EV473971339US

Sheet 2 of 3

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

6750-189-999

APPLICATION NO.

10/567,702

APPLICANT

Richard Kim

U.S. FILING DATE

August 21, 2006

ART UNIT

1642

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published) | T |
|-------------------|---|---|
| C19 | GENBANK Accession No. AF041792, "Gallus gallus tyrosine kinase ERBB-4 (ERBB4) mRNA, partial cds." | |
| C20 | GENBANK Accession No. M11762, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 2." | |
| C21 | GENBANK Accession No. M11763, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 3." | |
| C22 | GENBANK Accession No. M11764, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 4." | |
| C23 | GENBANK Accession No. M11765, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 5." | |
| C24 | GENBANK Accession No. M11766, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 6." | |
| C25 | GENBANK Accession No. M11767, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 7 and partial cds." | |
| C26 | GOLDSTEIN et al., 1995, "Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model." <i>Clin. Cancer Res.</i> 1:1311-8 | |
| C27 | GOUSTIN et al, 1986, "Growth factors and cancer." <i>Cancer Res</i> 46: 1015-29 | |
| C28 | HANCOCK et al., 1991, "A monoclonal antibody against the c-ErbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines." <i>Cancer Res.</i> 51:4575-80 | |
| C29 | LOGAN & SHENK, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection." <i>Proc. Natl. Acad. Sci USA</i> 81:3655 | |
| C30 | NOONBERG et al., 2000, "Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents." <i>Drugs</i> 59:753-67 | |
| C31 | OLAYIOYE et al., 2000, "The ErbB signaling network: receptor heterodimerization in development and cancer." <i>EMBO J.</i> 19:3159-67 | |
| C32 | PLOWMAN et al., 1990, "Molecular cloning and expression of an additional epidermal growth factor receptor-related gene." <i>Proc. Natl. Acad. Sci USA</i> 87:4905-9 | |
| C33 | PLOWMAN et al., 1993, "Ligand-specific activation of HER4/p180 ^{erbB4} , a fourth member of the epidermal growth factor receptor family." <i>Proc. Natl. Acad. Sci USA</i> 90:1746-50 | |
| C34 | PREWETT et al., 1996, "The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma." <i>J. Immunother. Tumor. Immunol.</i> 19: 419-427 | |
| C35 | SAMPSON et al., 2000, "Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors." <i>Proc. Natl. Acad. Sci. USA</i> 97:7503-8 | |
| C36 | SCHLESSINGER, 2000, "Cell signaling by receptor tyrosine kinases." <i>Cell</i> 103:211-225 | |
| C37 | SEDLACEK, 2000, "Kinase inhibitors in cancer therapy: a look ahead." <i>Drugs</i> 59:435-76 | |
| C38 | SIMON, 2000, "Receptor Tyrosine Kinases: Specific Outcomes from General Signals" <i>Cell</i> 103:13-15 | |
| C39 | TANG C.K. & LIPPMAN, M.E. in <i>Hormones and Signaling</i> , ed. O'Malley, B.W., 113-165, Academic Press, San Diego | |
| C40 | ULRICH et al., 1984, "Search for selectivity in interactions of chiral solvated electrons." <i>Nature</i> 309:418-425 | |
| C41 | WELLS, 1999, "EGF receptor" <i>Int. J. Biochem & Cell Biol.</i> 31:637-43 | |
| C42 | WOODBURN, 1999, "The epidermal growth factor receptor and its inhibition in cancer therapy." <i>Pharmacol. Ther.</i> 82:241-50 | |

EXAMINER
NYI-3927254v1

/Anne Holleran/

DATE CONSIDERED

12/22/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./



Express Mail No.: EV473971339US
Sheet 3 of 3

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.
6750-189-999

APPLICATION NO.
10/567,702

APPLICANT
Richard Kim

U.S. FILING DATE
August 21, 2006

ART UNIT
1642

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published) | T |
|----------------------|-----|---|---|
| | C43 | YANG et al., 2000, "Therapeutic Potential of ABX-EGF, a Fully Human Anti-EGF Receptor Monoclonal Antibody, for Cancer Treatment." <i>Proc. Am. Soc. Clin. Oncol.</i> 19:48 | |
| | C44 | ZHANG et al., 1997, "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4." <i>Proc. Natl. Acad Sci USA</i> 94: 9562-7 | |

EXAMINER
NY1-3927254v1

/Anne Holleran/

DATE CONSIDERED

12/22/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--|-----------------|------------------|--|--|
| *Examiner Initial | | Document Number | Date mm/dd/yy | Name Of Patentee Or Applicant Of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--|--|------------------|--|---|---|
| | | Foreign Patent Document Country Code, Number, Kind Code (If Known) | Date mm/dd/yy | Name Of Patentee Or Applicant Of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T |
| | | | | | | |

[illegible]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./

| | | |
|--|-------------------------------------|-------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. 6750-189-999 | APPLICATION NO. 10/567,702 |
| | APPLICANT Richard Kim | |
| | U.S. FILING DATE August 21, 2006 | ART UNIT 1643 |

| U.S. PATENT DOCUMENTS | | | | |
|-----------------------|-----------------|---------------|---|---|
| * Examiner Initial | Document Number | Date mm/dd/yy | Name Of Patentee Or Applicant Of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear |
| | | | | |

| FOREIGN PATENT DOCUMENTS | | | | |
|--|---------------|---|---|---|
| Foreign Patent Document Country Code, Number, Kind Code (If Known) | Date mm/dd/yy | Name Of Patentee Or Applicant Of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T |
| | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----|---|--|---|
| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published) | | T |
| /A.H./ | C48 | ANDERSON et al., 2002, "ErbB receptor tyrosine kinase inhibitors as therapeutic agents" <i>Front. Biosci.</i> 7:d1926-d1940 | | |
| /A.H./ | C49 | CAPPUZZO et al., 2003, "Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC" <i>J. Clin. Oncol.</i> 21:2658-2663 | | |
| /A.H./ | C50 | CHEN et al. 2000, "Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3" <i>Biochem. Biophys. Res. Comm.</i> 277: 757-763 | | |
| /A.H./ | C51 | CHRISTENSEN et al., 2001, "High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo" <i>Clin. Cancer Res.</i> 7:4230-4238 | | |
| /A.H./ | C52 | CLASSEN et al., 2002, "Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy" <i>Tumor Biol.</i> 23:70-75 | | |
| /A.H./ | C53 | NICHOLSON et al., 1993, "Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity" <i>Eur. J. Cancer</i> 29A:1018-1023 | | |
| /A.H./ | C54 | PATERSON et al., 1991, "Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer" <i>Cancer Res.</i> 51:556-567 | | |
| /A.H./ | C55 | XIA et al., 1999, "Combination of EGFR, HER-2/neu and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members" <i>Clin. Cancer Res.</i> 5:4164-4174 | | |

| | | |
|---|-----------------|-------------------------------|
| EXAMINER NYI-136908v1 | /Anne Holleran/ | DATE CONSIDERED 12/14/2008 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./